{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:06:11Z","timestamp":1788951971056,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.018","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:07:39Z","timestamp":1784304459000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Immunotherapy Addition on Dose Density and Clinical Outcomes of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Retrospective, Real-world Study From Multiple Centers in London, UK"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5753-1569","authenticated-orcid":false,"given":"Rooman","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesel","family":"Veli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Fessas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Koske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosire","family":"Oroko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqayah","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juned","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaman","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Sheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Konstantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fharat","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisavet","family":"Papadimitraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clbc.2026.07.018_bib0001","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2011negative breast cancer therapy: current and future perspectives (review)","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clbc.2026.07.018_bib0002","unstructured":"Cancer Research UK. 2024. Breast cancer statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer#heading-Zero. Accessed June 15, 2026"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.018_bib0003","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2026.07.018_bib0004","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.018_bib0005","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","article-title":"Pathological complete response in neoadjuvant treatment of breast cancer","volume":"22","author":"Cortazar","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.018_bib0006","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clbc.2026.07.018_bib0007","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.018_bib0008","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.clbc.2026.07.018_bib0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2026.44.16_suppl.507","article-title":"Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: final analysis results from the phase 3 KEYNOTE-522 study","volume":"44","author":"Schmid","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.018_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","article-title":"Toxicities associated with PD-1\/PD-L1 blockade","volume":"24","author":"Wang","year":"2018","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.018_bib0011","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.018_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.26252","article-title":"Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials: a systematic review and meta-analysis","volume":"5","author":"Pala","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.018_bib0013","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers13010103","article-title":"Use of a cancer registry to evaluate patient-reported outcomes of immune checkpoint inhibitors","volume":"13","author":"Jim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.018_bib0014","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cllc.2020.04.003","article-title":"A population-based study of immunotherapy-related toxicities in lung cancer","volume":"21","author":"Cathcart-Rake","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.018_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104494","article-title":"Immune-related adverse events are associated with better event-free survival in a phase I\/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer","volume":"10","author":"Rios-Hoyo","year":"2025","journal-title":"ESMO Open"},{"issue":"22","key":"10.1016\/j.clbc.2026.07.018_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17223675","article-title":"Prognostic significance of endocrine-related adverse events in patients with melanoma, non-small cell lung cancer and urothelial cancer after treatment with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"17","author":"Kopanos","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.018_bib0017","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.018_bib0018","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.018_bib0019","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.clbc.2026.07.018_bib0020","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","article-title":"OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (\u00b1 capecitabine) for residual triple-negative breast cancer","volume":"20","author":"Tolaney","year":"2024","journal-title":"Future Oncol"},{"issue":"9_Supplement","key":"10.1016\/j.clbc.2026.07.018_bib0021","doi-asserted-by":"crossref","first-page":"PO4-19-05","DOI":"10.1158\/1538-7445.SABCS23-PO4-19-05","article-title":"OptimICE\u2011pCR: de\u2011escalation of therapy in early\u2011stage triple\u2011negative breast cancer patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)","volume":"84","author":"Tolaney","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.018_bib0022","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.018_bib0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.clbc.2026.07.018_bib0024","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2026.44.16_suppl.570","volume":"44","author":"Dooley","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.018_bib0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","volume":"36","author":"Mart\u00edn","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:06:37Z","timestamp":1788948397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1526820926001199"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.018","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Immunotherapy Addition on Dose Density and Clinical Outcomes of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Retrospective, Real-world Study From Multiple Centers in London, UK","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}